Company commences Technegas trial in U.S.

11/20/2012 | ProactiveInvestors.co.au (Australia)

Cyclopharm has enrolled the first patient in a U.S. clinical trial involving its Technegas product, a gas inhaled by patients before imaging to improve detection of blood clots in the lungs. The multi-center study will eventually involve 750 patients and is expected to be completed in 18 months.

View Full Article in:

ProactiveInvestors.co.au (Australia)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA